COMMUNIQUÉS West-GlobeNewswire

Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
09/09/2026
Complementary Technologies Deliver an Integrated, End-to-End Clinical Flow Cytometry Workflow for Laboratories Across Europe FREMONT, Calif., and HAMBURG, Germany, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Sysmex Europe SE , a [...]
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
09/09/2026
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the [...]
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
09/09/2026
Open-label, two-part dose-escalation and dose-expansion study planned in up to 50 patients with advanced solid tumors across Australia MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. ( [...]
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
09/09/2026
Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc [...]
ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders
09/09/2026
Now shipping to UPPI, ENvue's exclusive distribution partner, following completion of the Company's U.S. manufacturing transition TYLER, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ENvue Medical , Inc. (NASDAQ: FEED) (“ [...]
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2
09/09/2026
- Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data – - Pharmacokinetic observations at the lowest dose evaluated were [...]
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
09/09/2026
CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT NEW YORK and TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” [...]
NervGen to Host Inaugural R&D Day on September 30, 2026
09/09/2026
R&D Day to feature an in-depth review of NVG-291, including its nonclinical and translational foundation, broader therapeutic potential, clinical data generated to date, perspectives from the SCI community, and the [...]
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
09/09/2026
CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers PHILADELPHIA, Sept [...]
Avicanna Launches MyMedi.ca Integrated Healthcare Program in Canada
09/09/2026
Integrating MyMedi.ca healthcare provider-guided medical cannabis care into hospitals, specialty clinics, insurers and multidisciplinary healthcare networks in Canada TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Avicanna [...]
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer
09/09/2026
Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished clinical, [...]
Kane Biotech to Host Commercial Update Webcast on September 16
09/09/2026
Board Chair Philip Renaud, leading wound-care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane’s commercial progress, clinical relevance and operational priorities WINNIPEG, Manitoba, Sept [...]
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
09/09/2026
Positive safety and favourable biodistribution seen in all subjects dosed Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake Data support the targeting potential of RAD301 and [...]
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
09/09/2026
OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement in visual [...]
Broncos Country, This One’s for You: Breckenridge Distillery Kicks Off Another Season with the Denver Broncos and a Limited-Edition Whiskey Collection Honoring “The Drive”
09/09/2026
Celebrating six seasons as a proud whiskey partner of the Denver Broncos, Breckenridge Distillery debuts a limited-edition Bourbon Whiskey lineup and Creamsicle Whiskey Seltzer built for Broncos Country, game-day [...]
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
09/09/2026
Independent studies conducted at Northwestern University and Mayo Clinic demonstrate synergistic activity of elraglusib in combination with RAS-targeted agents across multiple murine and human pancreatic cancer models [...]
MapLight Therapeutics to Participate in Upcoming Investor Conference
09/09/2026
SAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference: Event : [...]
Remix Therapeutics Appoints Nicole Sweeny as Chief Commercial Officer
09/09/2026
Accomplished Industry Executive to Lead Commercial Strategy and Launch Readiness WATERTOWN, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing [...]
Onco360® Has Been Selected as Part of an Ultra-Narrow Specialty Pharmacy Network for MIMRYLO™ (rusfertide)
09/09/2026
LOUISVILLE, Ky., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected by Takeda Pharmaceuticals as an ultra-narrow limited distribution partner for [...]

Pages